Anaplastic Astrocytoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: ANP005 MIFTS: 59	Anaplastic Astrocytoma Categories: Cancer diseases, Mental diseases, Neuronal diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Anaplastic Astrocytoma

MalaCards integrated aliases for Anaplastic Astrocytoma:

Name: Anaplastic Astrocytoma ¹¹ ¹⁹ ⁵⁸ ⁵³ ¹⁴ ¹⁶ ⁷¹ ⁷⁵

Astrocytoma, Anaplastic ²⁸ ⁵

Grade Iii Astrocytoma ¹¹ ¹⁹

Grade Iii Astrocytic Tumor ¹¹

Characteristics:

Prevelance:

1-9/1000000 (United States) ⁵⁸

Age Of Onset:

Adult ⁵⁸

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Neuronal diseases Mental diseases

See all MalaCards categories (disease lists)

ICD10: ³²

Neoplasms

Malignant neoplasms of eye, brain and other parts of central nervous system

Malignant neoplasm of brain

Malignant neoplasm: Brain, unspecified

Orphanet: ⁵⁸

Rare neurological diseases

External Ids:

Disease Ontology ¹¹ DOID:3078

MeSH ⁴³ D001254

NCIt ⁴⁹ C9477

SNOMED-CT ⁶⁸ 55353007

ICD10 via Orphanet ³² C71.9

UMLS via Orphanet ⁷² C0334579

Orphanet ⁵⁸ ORPHA251589

EFO ¹⁶ EFO_0002499

UMLS ⁷¹ C0334579

Sources

Summaries for Anaplastic Astrocytoma

Orphanet: ⁵⁸ A rare, high-grade, malignant glial tumor, histologically characterized by abundance of pleomorphic astrocytes and multiple mitotic figures, often associated with diffuse infiltration of the surrounding tissue, considerable edema and mass effect and involvement of the contralateral brain. Depending on the primary localization of the tumor, patients can present with signs of raised intracranial pressure (headache, vomiting, papilledema), seizures, progressive neurological deficits, and/or behavioral changes. The tumor is most commonly localized in the frontal and temporal lobes, brain stem and spinal cord.

MalaCards based summary: Anaplastic Astrocytoma, also known as astrocytoma, anaplastic, is related to idh-mutant anaplastic astrocytoma and idh-wildtype anaplastic astrocytoma, and has symptoms including headache, seizures and motor manifestations. An important gene associated with Anaplastic Astrocytoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are ERK Signaling and Disease. The drugs Dabrafenib and Procarbazine have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and eye, and related phenotypes are Reduced mammosphere formation and Decreased viability in pancreas lineage

GARD: ¹⁹ Anaplastic astrocytoma is a rare, cancerous (malignant) type of brain tumor that arises from star-shaped brain cells called astrocytes. These cells surround and protect nerve cells in the brain and spinal cord. Signs and symptoms vary depending on the location and size of the tumor and may include headaches, drowsiness, vomiting, and changes in personality or mental status. Some affected people have seizures, vision problems, weakness of the limbs, and/or coordination problems. Anaplastic astroctyomas usually occur sporadically but can be associated with a few rare, genetic disorders.

Disease Ontology: ¹¹ A malignant astrocytoma that is characterized by cells with regular, round to oval nuclei.

Wikipedia: ⁷⁵ Anaplastic astrocytoma is a rare WHO grade III type of astrocytoma, which is a type of cancer of the... more...

Sources

Related Diseases for Anaplastic Astrocytoma

Diseases related to Anaplastic Astrocytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 503)

#	Related Disease	Score	Top Affiliating Genes
1	idh-mutant anaplastic astrocytoma	33.1	MGMT IDH2 ATRX
2	idh-wildtype anaplastic astrocytoma	33.1	MGMT IDH2 ATRX
3	astrocytoma, idh-mutant, grade 4	32.5	PDGFRA MGMT IDH2 ATRX
4	high grade glioma	31.5	VEGFA TP53 PTEN PDGFRA MGMT MDM2
5	glioblastoma	31.5	VEGFA TP53 PTEN PDGFRA OLIG2 MGMT
6	brain cancer	31.3	VEGFA TP53 PTEN PDGFRA OLIG2 OLIG1
7	glioma	31.3	TP53 PTEN MGMT MDM2 IDH2 EGFR
8	malignant astrocytoma	31.2	VEGFA TP53 PTEN MGMT EGFR ATRX
9	high-grade astrocytoma	31.2	TP53 PTEN ATRX
10	oligoastrocytoma	31.2	MGMT IDH2 GFAP
11	neurofibromatosis, type i	31.0	TP53 PTEN PDGFRA EGFR CDKN2A
12	neurofibromatosis	31.0	VEGFA TP53 PTEN PDGFRA EGFR CDKN2A
13	enchondromatosis, multiple, ollier type	30.9	TP53 IDH2 ATRX
14	bap1 tumor predisposition syndrome	30.9	TP53 PTEN EGFR CDKN2A CDK4
15	adenoma	30.9	TP53 MGMT CDKN2A CCND1
16	atypical teratoid rhabdoid tumor	30.9	TP53 OLIG2 GFAP EGFR CDKN2A CCND1
17	diffuse astrocytoma	30.8	TP53 PTEN PDGFRA OLIG2 MGMT IDH2
18	inherited cancer-predisposing syndrome	30.8	TP53 PTEN EGFR CDKN2A CDK4
19	hydrocephalus	30.8	VEGFA TP53 PTEN GFAP
20	myelodysplastic syndrome	30.8	VEGFA TP53 PDGFRA IDH2 CDKN2B CDKN2A
21	pilocytic astrocytoma	30.7	TP73 TP53 PTEN PDGFRA OLIG2 MGMT
22	medulloblastoma	30.7	VEGFA TP73 TP53 PTEN PDGFRA OLIG2
23	meningioma, familial	30.7	VEGFA TP73 TP53 S100A5 PTEN OLIG2
24	low grade glioma	30.7	VEGFA TP53 PTEN PDGFRA OLIG2 MGMT
25	leukemia, acute lymphoblastic	30.7	TP73 TP53 CDKN2B CDKN2A CDK4
26	anaplastic pleomorphic xanthoastrocytoma	30.6	OLIG2 MGMT ATRX
27	mismatch repair cancer syndrome	30.6	TP53 PTEN MGMT
28	plexiform neurofibroma	30.6	TP53 PDGFRA EGFR CDKN2A
29	choroid plexus cancer	30.6	TP53 OLIG2 GFAP ATRX
30	leukemia, chronic myeloid	30.6	VEGFA TP53 PTEN PDGFRA EGFR CDKN2B
31	pleomorphic xanthoastrocytoma	30.6	TP53 MGMT IDH2 CDKN2A ATRX
32	diffuse midline glioma, h3 k27m-mutant	30.6	TP53 PDGFRA OLIG2 MGMT ATRX
33	hemangioma	30.6	VEGFA TP53 PTEN EGFR CDKN2A
34	hemangioblastoma	30.6	VEGFA PDGFRA GFAP EGFR
35	oligodendroglioma	30.5	VEGFA TP73 TP53 PTEN PDGFRA OLIG2
36	neurofibroma	30.5	VEGFA TP53 PTEN PDGFRA EGFR CDKN2A
37	paraganglioma	30.5	IDH2 GFAP EGFR CDKN2A CCND1 ATRX
38	gliomatosis cerebri	30.5	TP53 PTEN OLIG2 MGMT IDH2 GFAP
39	fanconi anemia, complementation group a	30.5	TP73 TP53 PTEN MDM2 CDKN2A ATRX
40	lynch syndrome	30.5	VEGFA TP53 PTEN MGMT EGFR CDKN2A
41	li-fraumeni syndrome	30.5	TP53 PTEN MDM2 EGFR CDKN2B CDKN2A
42	skin disease	30.5	VEGFA TP53 PTEN EGFR CDKN2A CCND1
43	spinal cord astrocytoma	30.5	IDH2 ATRX
44	rhabdomyosarcoma 2	30.4	TP53 MDM2 CDK4
45	idh-wildtype glioblastoma	30.4	TP53 PTEN PDGFRA OLIG2 MGMT IDH2
46	gliosarcoma	30.4	VEGFA TP53 PTEN PDGFRA OLIG2 MGMT
47	renal cell carcinoma, nonpapillary	30.4	VEGFA TP53 PTEN PDGFRA MDM2 EGFR
48	mixed glioma	30.4	TP53 PTEN PDGFRA OLIG2 MGMT IDH2
49	melanoma	30.4	VEGFA TP53 PTEN PDGFRA MGMT MDM2
50	anaplastic oligodendroglioma	30.4	VEGFA TP53 PTEN PDGFRA OLIG2 OLIG1

Graphical network of the top 20 diseases related to Anaplastic Astrocytoma:

Sources

Symptoms & Phenotypes for Anaplastic Astrocytoma

UMLS symptoms related to Anaplastic Astrocytoma:

headache; seizures; motor manifestations; sensory manifestations

GenomeRNAi Phenotypes related to Anaplastic Astrocytoma according to GeneCards Suite gene sharing:

²⁵

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	no effect	GR00402-S-1	10.15	ATRX CCND1 CDK4 CDKN2A CDKN2B DMBT1
2	no effect	GR00402-S-2	10.15	ATRX CDK4 CDKN2A CDKN2B DMBT1 EGFR
3	Reduced mammosphere formation	GR00396-S	9.56	ATRX CCND1 CDK4 EGFR IDH2 MCM3
4	Decreased viability in pancreas lineage	GR00235-A	9.16	CCND1 TP53

MGI Mouse Phenotypes related to Anaplastic Astrocytoma:

⁴⁵ (show all 25)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	neoplasm	MP:0002006	10.52	CCND1 CDK4 CDKN2A CDKN2B DMBT1 EGFR
2	nervous system	MP:0003631	10.5	ATRX CCND1 CDK4 CDKN2A EGFR GFAP
3	homeostasis/metabolism	MP:0005376	10.47	CCND1 CDK4 CDKN2A CDKN2B DMBT1 EGFR
4	cellular	MP:0005384	10.45	ATRX CCND1 CDK4 CDKN2A CDKN2B DMBT1
5	growth/size/body region	MP:0005378	10.43	ATRX CCND1 CDK4 CDKN2A EGFR GFAP
6	endocrine/exocrine gland	MP:0005379	10.36	CCND1 CDK4 CDKN2A CDKN2B EGFR MCM3
7	normal	MP:0002873	10.31	CCND1 CDK4 EGFR GFAP MDM2 PDGFRA
8	embryo	MP:0005380	10.31	ATRX CDK4 CDKN2A DMBT1 EGFR MCM3
9	digestive/alimentary	MP:0005381	10.3	CCND1 CDK4 CDKN2A DMBT1 EGFR GFAP
10	cardiovascular system	MP:0005385	10.29	ATRX CCND1 CDK4 CDKN2A EGFR GFAP
11	muscle	MP:0005369	10.28	CDK4 CDKN2A EGFR GFAP MDM2 OLIG2
12	immune system	MP:0005387	10.28	CCND1 CDK4 CDKN2A CDKN2B DMBT1 EGFR
13	behavior/neurological	MP:0005386	10.27	ATRX CCND1 CDK4 CDKN2A GFAP MDM2
14	no phenotypic analysis	MP:0003012	10.26	CDKN2A CDKN2B EGFR MDM2 MGMT OLIG2
15	renal/urinary system	MP:0005367	10.24	CDK4 CDKN2B DMBT1 EGFR MDM2 PDGFRA
16	liver/biliary system	MP:0005370	10.18	CDK4 CDKN2A EGFR MCM3 MDM2 PTEN
17	pigmentation	MP:0001186	10.17	CDK4 CDKN2A EGFR MDM2 PDGFRA PTEN
18	reproductive system	MP:0005389	10.15	ATRX CCND1 CDK4 CDKN2A CDKN2B EGFR
19	craniofacial	MP:0005382	10.11	CCND1 CDK4 EGFR MDM2 PDGFRA TP53
20	respiratory system	MP:0005388	10.1	CCND1 CDKN2A EGFR MGMT OLIG2 PDGFRA
21	skeleton	MP:0005390	10.1	CCND1 CDK4 CDKN2A EGFR IDH2 MDM2
22	vision/eye	MP:0005391	10	ATRX CCND1 CDK4 CDKN2A EGFR GFAP
23	hematopoietic system	MP:0005397	9.97	CCND1 CDK4 CDKN2A CDKN2B EGFR IDH2
24	mortality/aging	MP:0010768	9.91	ATRX CCND1 CDK4 CDKN2A CDKN2B DMBT1
25	integument	MP:0010771	9.4	CCND1 CDK4 CDKN2A CDKN2B EGFR MCM3

Sources

Drugs & Therapeutics for Anaplastic Astrocytoma

Drugs for Anaplastic Astrocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 197)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Dabrafenib

Approved, Investigational

Phase 4

1195765-45-7

44462760

Procarbazine

Approved, Investigational

Phase 3

671-16-9

4915

Benzocaine

Approved, Investigational

Phase 3

1994-09-7, 94-09-7

2337

Tannic acid

Approved

Phase 3

1401-55-4

16129878 16129778

Valproic acid

Approved, Investigational

Phase 3

99-66-1

3121

Eflornithine

Approved, Withdrawn

Phase 3

70052-12-9

3009

Lomustine

Approved, Investigational

Phase 3

13010-47-4

3950

Bevacizumab

Approved, Investigational

Phase 2, Phase 3

216974-75-3

135329020

Fluorouracil

Approved

Phase 2, Phase 3

51-21-8

3385

Ornithine

Approved, Nutraceutical

Phase 3

3184-13-2, 70-26-8

6262

Semustine

Experimental, Investigational

Phase 3

13909-09-6

5198

Trabedersen

Investigational

Phase 3

925681-61-4

Interferon-alpha

Phase 3

Anticonvulsants

Phase 3

Pharmaceutical Solutions

Phase 3

Psychotropic Drugs

Phase 3

Antiprotozoal Agents

Phase 3

Antiparasitic Agents

Phase 3

Immunoglobulin G

Phase 2, Phase 3

Endothelial Growth Factors

Phase 2, Phase 3

Antineoplastic Agents, Immunological

Phase 2, Phase 3

Mitogens

Phase 3

Angiogenesis Inhibitors

Phase 2, Phase 3

Iodine

Approved, Investigational

Phase 2

7553-56-2

807

Sunitinib

Approved, Investigational

Phase 2

557795-19-4

5329102

Carmustine

Approved, Investigational

Phase 2

154-93-8

2578

Leflunomide

Approved, Investigational

Phase 2

75706-12-6

3899

Topotecan

Approved, Investigational

Phase 2

123948-87-8, 119413-54-6

60699 60700

Paclitaxel

Approved, Vet_approved

Phase 2

33069-62-4

36314

Cisplatin

Approved

Phase 2

15663-27-1

2767 5702198 441203

Aflibercept

Approved

Phase 2

862111-32-8

124490314

Lapatinib

Approved, Investigational

Phase 1, Phase 2

231277-92-2, 388082-78-8

208908

Romidepsin

Approved, Investigational

Phase 1, Phase 2

128517-07-7

5352062

Gefitinib

Approved, Investigational

Phase 1, Phase 2

184475-35-2

123631

Mercaptopurine

Approved

Phase 2

50-44-2

667490

Streptozocin

Approved, Investigational

Phase 2

18883-66-4, 66395-18-4

29327

Nintedanib

Approved

Phase 2

656247-17-5

135423438 9809715

Dimethyl sulfoxide

Approved, Vet_approved

Phase 2

67-68-5

679

Etoposide

Approved

Phase 2

33419-42-0

36462

Valaciclovir

Approved, Investigational

Phase 1, Phase 2

124832-27-5, 124832-26-4

60773 135398742

Sodium citrate

Approved, Investigational

Phase 1, Phase 2

68-04-2

23431961

Mebendazole

Approved, Vet_approved

Phase 1, Phase 2

31431-39-7

4030

Piperazine

Approved, Vet_approved

Phase 1, Phase 2

110-85-0

4837

Pembrolizumab

Approved

Phase 1, Phase 2

1374853-91-4

254741536

Vincristine

Approved, Investigational

Phase 2

2068-78-2, 57-22-7

5978

Sorbitol

Approved, Investigational

Phase 1, Phase 2

69-65-8, 50-70-4

453 6251 5780

Carboplatin

Approved

Phase 1, Phase 2

41575-94-4

10339178 38904

Cetuximab

Approved

Phase 1, Phase 2

205923-56-4

Palbociclib

Approved, Investigational

Phase 2

571190-30-2

5330286

Doxorubicin

Approved, Investigational

Phase 2

23214-92-8

31703

Interventional clinical trials:

(show top 50) (show all 193)

#	Name	Status	NCT ID	Phase	Drugs
1	An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib)	Recruiting	NCT03975829	Phase 4	dabrafenib;trametinib
2	Phase 3 Study of Carmustine Sustained Release Implant (CASANT) to Treat Newly Diagnosed Malignant Glioma	Unknown status	NCT01656980	Phase 3	Carmustine
3	A Single-blind, Randomized, Clinical Trial Comparing the Efficacy of 6 Cycles Versus 12 Cycles Temozolomide Regimens in Adjuvant Treatment of Patients With Brain High Grade Glioma	Unknown status	NCT03633552	Phase 3	Temozolomide
4	A Phase III Trial on Adjuvant Standard Temozolomide Chemotherapy With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas	Unknown status	NCT01765088	Phase 3	Temozolomide;α-IFN
5	A Multicenter, Open-Label, Randomized, Active-Controlled Parallel Groups Study Comparing the Efficacy and Safety of Temodal vs Semustine in the Treatment of Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma	Completed	NCT00335075	Phase 3	Temozolomide;Semustine
6	A Phase III Randomized Study (Phase I Closed) of Radiation Therapy and Temozolomide Versus Radiation Therapy and Nitrosourea for Anaplastic Astrocytoma And Mixed Anaplastic Oligoastrocytoma (Astrocytoma Dominant)	Completed	NCT00004259	Phase 3	BCNU 80mg/m2;TMZ 200mg/m2;CCNU;BCNU 150mg/m2;BCNU 200mg/m2;TMZ 150mg/m2 six 6-week cycles;TMZ 150mg/m2 six 8-week cycles
7	NOA-04 Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide	Completed	NCT00717210	Phase 3	Temozolomide
8	Radiotherapy for Malignant Astrocytomas in the Elderly	Completed	NCT00430911	Phase 3	Radiotherapy
9	Temozolomid (One Week on/One Week Off) Versus Strahlentherapie in Der Primärtherapie Anaplastischer Astrozytome Und Glioblastome Bei älteren Patienten: Eine Randomisierte Phase III-Studie (Methvsalem)	Completed	NCT01502241	Phase 3	Temozolomide
10	A Study on β-elemene as Maintain Treatment for Complete Remission Patients of Newly Diagnosed Malignant Gliomas Following Standard Treatment	Recruiting	NCT02629757	Phase 3	β-elemene
11	International Cooperative Phase III Trial of the HIT-HGG Study Group for the Treatment of High Grade Glioma, Diffuse Intrinsic Pontine Glioma, and Gliomatosis Cerebri in Children and Adolescents < 18 Years.(HIT-HGG-2013)	Recruiting	NCT03243461	Phase 3	Temozolomide + Valproic Acid
12	A Randomized Phase 3 Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine With Lomustine Compared to Lomustine Alone in Patients With AA That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy	Active, not recruiting	NCT02796261	Phase 3	Eflornithine;Lomustine
13	A Randomized Phase II/III Study of Vorinostat and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab and Local Irradiation Followed by Maintenance Bevacizumab and Temozolomide in Children With Newly Diagnosed High-Grade Gliomas	Active, not recruiting	NCT01236560	Phase 2, Phase 3	Temozolomide;Vorinostat
14	Efficacy and Safety of AP 12009 in Adult Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma as Compared to Standard Chemotherapy Treatment: A Randomized, Actively Controlled, Open Label Clinical Phase III Study.	Terminated	NCT00761280	Phase 3	trabedersen;temozolomide;carmustine;lomustine
15	A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma	Terminated	NCT02414165	Phase 2, Phase 3	Toca FC;Lomustine;Temozolomide
16	A Phase II/III Randomized, Open-Label Study of Toca 511, A Retroviral Replicating Vector, Combined With Toca FC With Temozolomide and Radiation Followed by Adjuvant Temozolomide and Toca FC Compared to Temozolomide and Radiation Followed by Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma	Withdrawn	NCT04105374	Phase 2, Phase 3	Extended Release Flucytosine;Temozolomide
17	A Phase II Open-Label, Multiple-Dose Study of Intracavitary Administered 131-I-TM-601 in Adult Patients With Recurrent High-Grade Glioma	Unknown status	NCT00114309	Phase 2	131-I-TM-601;131I-TM601
18	Phase I/II Clinical Trial of the Safety, Tolerability, and Anti-tumor Efficacy of the IGF-1R Inhibitor, AXL1717 (Picropodophyllin), in the Treatment of Recurrent Malignant Astrocytomas	Unknown status	NCT01721577	Phase 1, Phase 2	AXL1717
19	A Phase II Study of Sunitinib (NSC# 736511) in Recurrent, Refractory or Progressive High Grade Glioma and Ependymoma Tumors in Pediatric and Young Adult Patients	Completed	NCT01462695	Phase 2	Sunitinib Malate
20	A Phase I/II Study of ABT-888, An Oral Poly(ADP-ribose) Polymerase Inhibitor, and Concurrent Radiation Therapy, Followed by ABT-888 and Temozolomide, in Children With Newly Diagnosed Diffuse Pontine Gliomas (DIPG)	Completed	NCT01514201	Phase 1, Phase 2	Temozolomide;Veliparib
21	SCH 52365 Phase II Clinical Study: A Study on the Efficacy and Safety of Monotherapy With SCH 52365 in Patients With First Relapsed Anaplastic Astrocytoma	Completed	NCT00783393	Phase 2	Temozolomide
22	A Phase IIa Safety and Light Dose-escalation Study in Patients With Primary or Recurrent/High-grade Glioma (Defined for the Purposes of the Protocol as Anaplastic Astrocytoma [AA] or Glioblastoma Multiforme [GBM]) Using the Litx™ System to Confirm the Zone of Tumor Destruction During the Intraoperative Treatment of Glioma	Completed	NCT00409214	Phase 2	LS11 (talaporfin sodium)
23	A Phase II Open Label Study of SU101 for Patients With Anaplastic Astrocytoma in First Relapse	Completed	NCT00003775	Phase 2	leflunomide
24	A Phase II Trial of Paclitaxel and Topotecan With Filgrastim in Patients With Recurrent or Refractory Glioblastoma Multiforme or Anaplastic Astrocytoma	Completed	NCT00002814	Phase 2	paclitaxel;topotecan hydrochloride
25	A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma Multiforme	Completed	NCT00606008	Phase 2	Sunitinib Malate
26	Phase II Trial of Pre-Irradiation Chemotherapy With BCNU, Cisplatin and Oral Etoposide Combined With Radiation Therapy in the Treatment of Grade 3 Astrocytoma (Anaplastic Astrocytoma)	Completed	NCT00003621	Phase 2	carmustine;cisplatin;etoposide
27	Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients With Anaplastic Astrocytoma	Completed	NCT00003470	Phase 2	Antineoplaston therapy (Atengenal + Astugenal)
28	A Phase II Study to Evaluate the Efficacy of Bevacizumab Plus Irinotecan in Recurrent Anaplastic Astrocytoma or Recurrent Glioblastoma Multiforme	Completed	NCT00921167	Phase 2	Bevacizumab/Irinotecan
29	Phase I/II Trial of Oral Erlotinib (Tarceva, OSI-774) for Treatment of Relapsed/Refractory Glioblastoma Multiforme and Anaplastic Astrocytoma	Completed	NCT00301418	Phase 1, Phase 2	Erlotinib
30	Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients With Anaplastic Astrocytoma	Completed	NCT00003537	Phase 2	Antineoplaston therapy (Atengenal + Astugenal)
31	BPA-Mediated Boron Neutron Capture Therapy (BNCT) in the Treatment of Glioblastoma or Anaplastic Astrocytoma Progressing After Conventional External Beam Radiotherapy	Completed	NCT00115440	Phase 1, Phase 2
32	Phase I Trial of Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma	Completed	NCT02942264	Phase 1, Phase 2	Zotiraciclib (TG02);Temozolomide (TMZ)
33	Cilengitide (EMD 121974) (IND# 59073) in Recurrent or Progressive and Refractory Childhood High-Grade Glioma	Completed	NCT00679354	Phase 2	cilengitide
34	Multi-national, Open-label, Active-controlled, Randomized Dose-finding Study to Evaluate Efficacy of 2 Doses of AP 12009 in Recurrent Glioma, Administered Intratumorally as Continuous High-flow Microperfusion Over 7 Days Every Other Week	Completed	NCT00431561	Phase 2	AP 12009 10 µM;AP 12009 80 µM;temozolomide or PCV
35	A Phase II Study of Bendamustine in the Treatment of Recurrent High-Grade Gliomas (Anaplastic Gliomas and Glioblastoma)	Completed	NCT00823797	Phase 2	Bendamustine Hydrochloride
36	A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage	Completed	NCT00492089	Phase 2	bevacizumab;placebo
37	A Phase 2 Trial of Tandutinib in Combination With Bevacizumab for Patients With Recurrent High-Grade Gliomas	Completed	NCT00667394	Phase 2	MLN-518 (Tandutinib)
38	A Pharmacokinetic and Phase 2 Study of Sunitinib Malate in Recurrent Malignant Gliomas	Completed	NCT00499473	Phase 2	sunitinib malate
39	Phase II Study of Bevacizumab Plus Irinotecan (Camptosar™) in Children With Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas, Ependymomas and Low Grade Gliomas	Completed	NCT00381797	Phase 2	Irinotecan Hydrochloride
40	Phase II Single Arm Trial of VEGF Trap in Patients With Recurrent Temozolomide-Resistant Malignant Gliomas	Completed	NCT00369590	Phase 2
41	A Phase I-II Trial of Depsipeptide in Patients With Recurrent High-Grade Gliomas	Completed	NCT00085540	Phase 1, Phase 2	depsipeptide
42	Pre-operative IL13-PE38QQR Infusion in Patients With Recurrent or Progressive Supratentorial Malignant Glioma: A Phase I/II Study	Completed	NCT00041587	Phase 1, Phase 2	IL13-PE38QQR
43	A Phase 2 Study of Valproic Acid and Radiation, Followed by Maintenance Valproic Acid and Bevacizumab in Children With Newly Diagnosed High-grade Gliomas or Brainstem Gliomas	Completed	NCT00879437	Phase 2	Valproic acid;Bevacizumab
44	Molecular Biology and Phase II Study of Lapatinib (GW572016) in Pediatric Patients With Recurrent or Refractory Medulloblastoma, Malignant Glioma or Ependymoma	Completed	NCT00095940	Phase 1, Phase 2	lapatinib ditosylate
45	A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas	Completed	NCT00995007	Phase 2	ZD6474 (Vandetanib);Carboplatin
46	Phase I/II Study of OSI-774 (Erlotinib) and CCI-779 (Temsirolimus) in Patients With Recurrent Malignant Glioma	Completed	NCT00112736	Phase 1, Phase 2	erlotinib;temsirolimus
47	Phase I/II Trial of Gefitinib and Radiation in Pediatric Patients Newly Diagnosed With Brain Stem Tumors or Incompletely Resected Supratentorial Malignant Gliomas With Phase II Limited to Brain Stem Tumors	Completed	NCT00042991	Phase 1, Phase 2	gefitinib
48	Phase I/II Trial of Temsirolimus and Perifosine for Recurrent or Progressive Malignant Gliomas	Completed	NCT01051557	Phase 1, Phase 2	Perifosine;Temsirolimus
49	A Phase I/II Trial of OSI-774 in Patients With Recurrent Malignant Gliomas and Malignant Gliomas Post Radiation Therapy	Completed	NCT00045110	Phase 1, Phase 2	erlotinib hydrochloride
50	Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma: Phase I/II Study	Completed	NCT00024570	Phase 1, Phase 2	IL13-PE38QQR

Search NIH Clinical Center for Anaplastic Astrocytoma

Sources

Genetic Tests for Anaplastic Astrocytoma

Genetic tests related to Anaplastic Astrocytoma:

#	Genetic test	Affiliating Genes
1	Astrocytoma, Anaplastic ²⁸

Sources

Anatomical Context for Anaplastic Astrocytoma

Organs/tissues related to Anaplastic Astrocytoma:

MalaCards : Brain, Spinal Cord, Eye, Bone Marrow, Endothelial, Bone, Breast

Sources

Publications for Anaplastic Astrocytoma

Articles related to Anaplastic Astrocytoma:

(show top 50) (show all 2274)

#	Title	Authors	PMID	Year
1	Proliferating cell nuclear antigen, p53 and micro vessel density: Grade II vs. Grade III astrocytoma. ⁵³ ⁶²	Malhan P...Husain M	20090216	2010
2	Concurrent sequence variation of TP53 and TP73 genes in anaplastic astrocytoma. ⁵³ ⁶²	Anselmo NP...Casartelli C	19876867	2009
3	Corneal verticillata after dual anti-epidermal growth factor receptor and anti-vascular endothelial growth factor receptor 2 therapy (vandetanib) for anaplastic astrocytoma. ⁵³ ⁶²	Yeh S...Smith JA	19512898	2009
4	Clinical implications and prognostic value of EMMPRIN/CD147 and MMP2 expression in pediatric gliomas. ⁵³ ⁶²	Gu J...Wang D	18795327	2009
5	Evidence-based adjuvant therapy for gliomas: current concepts and newer developments. ⁵³ ⁶²	Khan MK...Chao ST	19346643	2009
6	Mutational inactivation of the nijmegen breakage syndrome gene (NBS1) in glioblastomas is associated with multiple TP53 mutations. ⁵³ ⁶²	Watanabe T...Ohgaki H	19151620	2009
7	Gene expression analysis of an EGFR indirectly related pathway identified PTEN and MMP9 as reliable diagnostic markers for human glial tumor specimens. ⁵³ ⁶²	Comincini S...Schinelli S	19657395	2009
8	MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma. ⁵³ ⁶²	Sadones J...Neyns B	18945611	2009
9	FoxM1B transcriptionally regulates vascular endothelial growth factor expression and promotes the angiogenesis and growth of glioma cells. ⁵³ ⁶²	Zhang Y...Huang S	18974115	2008
10	PTEN signaling pathways in glioblastoma. ⁵³ ⁶²	Koul D	18836294	2008
11	Serum GFAP is a diagnostic marker for glioblastoma multiforme. ⁵³ ⁶²	Jung CS...Sitzer M	17998256	2007
12	Aberrant FoxM1B expression increases matrix metalloproteinase-2 transcription and enhances the invasion of glioma cells. ⁵³ ⁶²	Dai B...Huang S	17404569	2007
13	Concurrent EGFR amplification and TP-53 mutation in glioblastomas. ⁵³ ⁶²	Gil-Benso R...Cerda-Nicolas M	17907599	2007
14	Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas. ⁵³ ⁶²	Ishii D...Yoshida J	17721049	2007
15	Epidermal growth factor receptor serum levels and prognostic value in malignant gliomas. ⁵³ ⁶²	Quaranta M...Troccoli G	17679463	2007
16	Clinical significance of ABCA2' a possible molecular marker for oligodendrogliomas. ⁵³ ⁶²	Soichi O...Jun-ichi K	17415208	2007
17	Molecular pathogenesis of pediatric astrocytic tumors. ⁵³ ⁶²	Nakamura M...Konishi N	17327574	2007
18	Association of mutant TP53 with alternative lengthening of telomeres and favorable prognosis in glioma. ⁵³ ⁶²	Chen YJ...Royds JA	16818615	2006
19	O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 Cohort. ⁵³ ⁶²	Pollack IF...Finlay JL	16849758	2006
20	Cytoplasmic, but not nuclear, p16 expression may signal poor prognosis in high-grade astrocytomas. ⁵³ ⁶²	Arifin MT...Kurisu K	16614947	2006
21	Serum IgE, tumor epidermal growth factor receptor expression, and inherited polymorphisms associated with glioma survival. ⁵³ ⁶²	Wrensch M...Prados MD	16618782	2006
22	Immunohistochemical estimation of cell cycle entry and phase distribution in astrocytomas: applications in diagnostic neuropathology. ⁵³ ⁶²	Scott IS...Coleman N	16150117	2005
23	Apolipoprotein D expression in primary brain tumors: analysis by quantitative RT-PCR in formalin-fixed, paraffin-embedded tissue. ⁵³ ⁶²	Hunter SB...Ou CY	16055749	2005
24	Lyn kinase activity is the predominant cellular SRC kinase activity in glioblastoma tumor cells. ⁵³ ⁶²	Stettner MR...Gladson CL	15994925	2005
25	Expression of endothelial nitric oxide synthase and vascular endothelial growth factor in association with neovascularization in human primary astrocytoma. ⁵³ ⁶²	Pan JW...Zhang M	15973775	2005
26	Molecular features of adult glioma associated with patient race/ethnicity, age, and a polymorphism in O6-methylguanine-DNA-methyltransferase. ⁵³ ⁶²	Wiencke JK...Wrensch M	16030116	2005
27	Apoptosis and proliferation: correlation with p53 in astrocytic tumours. ⁵³ ⁶²	Sarkar C...Sinha S	15981097	2005
28	Minichromosome maintenance protein 3 elicits a cancer-restricted immune response in patients with brain malignancies and is a strong independent predictor of survival in patients with anaplastic astrocytoma. ⁵³ ⁶²	Soling A...Rainov NG	15671553	2005
29	Brainstem gliomas--a clinicopathological study of 45 cases with p53 immunohistochemistry. ⁵³ ⁶²	Badhe PB...Mehta NK	15659871	2004
30	Clinicopathological study of diffuse type brainstem gliomas: analysis of 40 autopsy cases. ⁵³ ⁶²	Yoshimura J...Takahashi H	12968803	2003
31	Growth factor receptor expression varies among high-grade gliomas and normal brain: epidermal growth factor receptor has excellent properties for interstitial fusion protein therapy. ⁵³ ⁶²	Liu TF...Frankel AE	12939468	2003
32	Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma. ⁵³ ⁶²	Salmaggi A...Boiardi A	12777082	2003
33	Correlation of molecular genetic analysis of p53, MDM2, p16, PTEN, and EGFR and survival of patients with anaplastic astrocytoma and glioblastoma. ⁵³ ⁶²	Ushio Y...Saya H	12700122	2003
34	Overexpression of vascular endothelial growth factor isoforms drives oxygenation and growth but not progression to glioblastoma multiforme in a human model of gliomagenesis. ⁵³ ⁶²	Sonoda Y...Pieper RO	12702589	2003
35	Molecular genetic analysis of phosphatase and tensin homolog and p16 tumor suppressor genes in patients with malignant glioma. ⁵³ ⁶²	Abdullah JM...Isa MN	15679305	2003
36	Recurrent astrocytic tumours--a study of p53 immunoreactivity and malignant progression. ⁵³ ⁶²	Sarkar C...Mehta VS	12389885	2002
37	Fibroblast growth factor receptor (FGFR) 4 correlated with the malignancy of human astrocytomas. ⁵³ ⁶²	Yamada SM...Matsumoto K	11958417	2002
38	Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas. ⁵³ ⁶²	Chaudhry IH...Roberts IS	11683943	2001
39	Elevated levels of cathepsin B in human glioblastoma cell lines. ⁵³ ⁶²	Konduri S...Rao JS	11494030	2001
40	PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. ⁵³ ⁶²	Smith JS...Jenkins RB	11504770	2001
41	[A case of glioblastoma associated with dissemination, secondary to intratumoral hemorrhage]. ⁵³ ⁶²	Okuno S...Sakaki T	11554096	2001
42	Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma. ⁵³ ⁶²	Sonoda Y...Pieper RO	11431323	2001
43	Characterisation of molecular alterations in microdissected archival gliomas. ⁵³ ⁶²	Walker C...Rossi ML	11355303	2001
44	Comparison of cyclin A and MIB-1 expression in astrocytic tumors using image-based cell analysis system. ⁵³ ⁶²	Ren Y...Tawfik O	11277408	2001
45	Regulation of the urokinase-type plasminogen activator receptor gene in different grades of human glioma cell lines. ⁵³ ⁶²	Bhattacharya A...Rao JS	11234878	2001
46	Promoter hypermethylation of the RB1 gene in glioblastomas. ⁵³ ⁶²	Nakamura M...Ohgaki H	11204276	2001
47	Regulation of the uPA gene in various grades of human glioma cells. ⁵³ ⁶²	Lakka SS...Rao JS	11115541	2001
48	Expression of hepatocyte growth factor and matrix metalloproteinase-2 in human glioma. ⁵³ ⁶²	Yano H...Sakai N	11517976	2001
49	Functional evaluation of p53 and PTEN gene mutations in gliomas. ⁵³ ⁶²	Kato H...Ishioka C	11051241	2000
50	Molecular genetic analysis of archival gliomas using diagnostic smears. ⁵³ ⁶²	Walker C...Broome J	11054184	2000

Sources

Genes for Anaplastic Astrocytoma

Genes related to Anaplastic Astrocytoma (3 elite genes):

(show top 50) (show all 67)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	TP53	Tumor Protein P53	Protein Coding	424.21	Pathogenic ⁵ DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	9839169 1336544 8599254 (more) 8337939 20090216 19876867 7494604 11550308 11355303 10063271 8108140 11504770 12700122 7494603 12389885 10741908 9042164 16875495 1346255 11764090 10666371 9815715 9341929 7536455 8118823 1758878 11051241 9225141 9529927 9370234 8965097 8682593 7477776 8123492 1501894 17917588 15269478 19716156 17721049 17327574 11048299 1686725 16818615 15981097 15659871 10079373 9407934 9049884 9815964 7534015 8397797 19435942 19151620 15175080 11724349 11175638 9485008 9115587 8676433 7582239 7903434 1349850 1886708 9887356 9577364 8583240 15455376 8529218 16776982
2	ATRX	ATRX Chromatin Remodeler	Protein Coding	407.72	Pathogenic ⁵ DISEASES inferred ¹⁴
3	IDH2	Isocitrate Dehydrogenase (NADP(+)) 2	Protein Coding	32.57	Orphanet ⁵⁸ DISEASES inferred ¹⁴	24993250 19228619 19554337 (more) 23109653 24149775 20714900 21075857
4	MDM2	MDM2 Proto-Oncogene	Protein Coding	29.23	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Functions (show sections)	12700122 12241107 7815080 (more) 9266437 8504413 16319692
5	MGMT	O-6-Methylguanine-DNA Methyltransferase	Protein Coding	24.54	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	9779706 17721049 15455376 (more) 7549044 17691113 14744281 16936459 18575733 17965865 19346643 1501894 16849758 18945611
6	EGFR	Epidermal Growth Factor Receptor	Protein Coding	24.26	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	17679463 11504770 10029453 (more) 1314448 19127042 8814167 12700122 16618782 8057151 9260461 9677449 19512898 15163002 8965097 20331873 16030116 15913199 11138928 7815080 17907599 12939468 19716156 17327574 16133418 15943037 11048299 17189383 16364761 9407934 8476201 1776845 11431323 15290895 1320666 16008822 16776982 1311022 8583240
7	PTEN	Phosphatase And Tensin Homolog	Protein Coding	23.37	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11504770 9690672 19657395 (more) 11355303 10560660 10702383 10096247 15679305 18836294 17504928 12700122 10666371 10433932 11054184
8	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	21.47	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	7987821 12700122 9000591 (more) 7582239 7534015 12173338 16614947 7497469 10666371 12185811
9	CDK4	Cyclin Dependent Kinase 4	Protein Coding	21.23	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Functions (show sections)	7987821 16319692 9161727
10	MCM3	Minichromosome Maintenance Complex Component 3	Protein Coding	17.29	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	15671553
11	TP73	Tumor Protein P73	Protein Coding	15.81	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	19876867 12241107 11494043
12	GFAP	Glial Fibrillary Acidic Protein	Protein Coding	15.58	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	14756441 1806058 1668298 (more) 19663312 7609842 8526753 11554096 7518371 1652162 7684178 8082240 17998256
13	OLIG2	Oligodendrocyte Transcription Factor 2	Protein Coding	14.48	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	14575240 14730454 17917751 (more) 17415208
14	OLIG1	Oligodendrocyte Transcription Factor 1	Protein Coding	12.76	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	14730454 14575240
15	CCND1	Cyclin D1	Protein Coding	12.61	DISEASES inferred ¹⁴ GeneCards inferred via : Functions (show sections)
16	VEGFA	Vascular Endothelial Growth Factor A	Protein Coding	12.61	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9669344 8616870 10741908 (more) 12777082 15973775 11683943 12702589 18719373 11507079 17318973 15088099 15700836 15175080 16158178
17	PDGFRA	Platelet Derived Growth Factor Receptor Alpha	Protein Coding	12.57	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	17189383 16319692 17327574 (more) 14730454
18	DMBT1	Deleted In Malignant Brain Tumors 1	Protein Coding	12.44	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	10433932 12168116
19	CDKN2B	Cyclin Dependent Kinase Inhibitor 2B	Protein Coding	12.34	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9000591
20	S100A5	S100 Calcium Binding Protein A5	Protein Coding	11.53	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9989446
21	MMP2	Matrix Metallopeptidase 2	Protein Coding	11.49	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	7630025 10896208 11517976 (more) 8521615 9708803 18795327
22	FOXM1	Forkhead Box M1	Protein Coding	11.26	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	18974115 17404569 16489016
23	S100A3	S100 Calcium Binding Protein A3	Protein Coding	10.87	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9989446
24	RB1	RB Transcriptional Corepressor 1	Protein Coding	10.44	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11204276 8548755 11764090 (more) 10079373 9161727 12185811
25	PDGFRB	Platelet Derived Growth Factor Receptor Beta	Protein Coding	9.93	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15994925
26	MMP9	Matrix Metallopeptidase 9	Protein Coding	9.91	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	8521611 19657395 10638966 (more) 10845554 9708803
27	PLAUR	Plasminogen Activator, Urokinase Receptor	Protein Coding	9.35	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	7747809 15894933 11234878 (more) 9879460
28	PLAU	Plasminogen Activator, Urokinase	Protein Coding	9.02	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	8033079 11115541 8159659 (more) 7747809 10914816 11776074 10844794
29	MKI67	Marker Of Proliferation Ki-67	Protein Coding	8.81	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	7511316
30	NES	Nestin	Protein Coding	8.61	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	16529857
31	IDH1	Isocitrate Dehydrogenase (NADP(+)) 1	Protein Coding	8.6	DISEASES inferred ¹⁴
32	CTSB	Cathepsin B	Protein Coding	8.57	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	7820956 11494030 12437133
33	LGALS3	Galectin 3	Protein Coding	8.51	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11678425 15605987
34	BSG	Basigin (Ok Blood Group)	Protein Coding	8.31	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	18795327
35	FLT1	Fms Related Receptor Tyrosine Kinase 1	Protein Coding	8.01	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15700836 9669344
36	IGFBP2	Insulin Like Growth Factor Binding Protein 2	Protein Coding	7.9	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	10485462
37	TERF1	Telomeric Repeat Binding Factor 1	Protein Coding	7.86	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11466501 11501837
38	H2AC18	H2A Clustered Histone 18	Protein Coding	7.8	DISEASES inferred ¹⁴ ¹⁴
39	TIMP2	TIMP Metallopeptidase Inhibitor 2	Protein Coding	7.75	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	7820957
40	MIR196A1	MicroRNA 196a-1	RNA Gene	7.62	DISEASES inferred ¹⁴ ¹⁴
41	ANXA2	Annexin A2	Protein Coding	7.59	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	1333884
42	FGFR4	Fibroblast Growth Factor Receptor 4	Protein Coding	7.51	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11958417 16198476
43	APOD	Apolipoprotein D	Protein Coding	7.33	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	16055749 11895042
44	KDM4C	Lysine Demethylase 4C	Protein Coding	7.33	DISEASES inferred ¹⁴ ¹⁴
45	H3-3A	H3.3 Histone A	Protein Coding	7.23	DISEASES inferred ¹⁴
46	H3-3B	H3.3 Histone B	Protein Coding	7.23	DISEASES inferred ¹⁴
47	TSPAN31	Tetraspanin 31	Protein Coding	7.19	GeneCards inferred via : Functions (show sections)
48	CCND2	Cyclin D2	Protein Coding	7.15	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	10416984
49	MIR10A	MicroRNA 10a	RNA Gene	7.14	DISEASES inferred ¹⁴ ¹⁴
50	SERPINA3	Serpin Family A Member 3	Protein Coding	7.02	DISEASES inferred ¹⁴ ¹⁴

Sources

Variations for Anaplastic Astrocytoma

ClinVar genetic disease variations for Anaplastic Astrocytoma:

⁵

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	TP53	NM_000546.6(TP53):c.733G>A (p.Gly245Ser)	SNV	Pathogenic	12365	rs28934575	GRCh37: 17:7577548-7577548 GRCh38: 17:7674230-7674230
2	ATRX	NM_000489.6(ATRX):c.5579A>G (p.Asn1860Ser)	SNV	Pathogenic	11724	rs45439799	GRCh37: X:76856021-76856021 GRCh38: X:77600552-77600552
3	TP53	NM_000546.6(TP53):c.844C>T (p.Arg282Trp)	SNV	Pathogenic	12364	rs28934574	GRCh37: 17:7577094-7577094 GRCh38: 17:7673776-7673776

Sources

Expression for Anaplastic Astrocytoma

Search GEO for disease gene expression data for Anaplastic Astrocytoma.

Sources

Pathways for Anaplastic Astrocytoma

Pathways related to Anaplastic Astrocytoma according to GeneCards Suite gene sharing:

(show top 50) (show all 68)

#	Super pathways	Score	Top Affiliating Genes
1	ERK Signaling ⁶⁴ Show member pathways ILK Signaling ⁶⁴ MAPK Signaling ⁶⁴ Molecular Mechanisms of Cancer ⁶⁴ Rho Family GTPases ⁶⁴	13.85	CCND1 CDK4 CDKN2A CDKN2B EGFR MDM2
2	Disease ⁶⁶ Show member pathways Infectious disease ⁶⁶	13.83	ATRX CCND1 CDK4 CDKN2A EGFR MDM2
3	Signal Transduction ⁶⁶	13.8	CCND1 CDK4 CDKN2B EGFR GFAP MDM2
4	GPCR Pathway ⁶⁴ Show member pathways Breast Cancer Regulation by Stathmin1 ⁶⁴ Estrogen Pathway ⁶⁴ NFAT in Immune Response ⁶⁴ P2Y Receptor Signaling ⁶⁴ Pancreatic Adenocarcinoma ⁶⁴ Paxillin Interactions ⁶⁴ Ras Pathway ⁶⁴	13.73	VEGFA TP53 PDGFRA MDM2 EGFR CDKN2B
5	Cell Cycle, Mitotic ⁶⁶ Show member pathways Cell Cycle ⁶⁶ M Phase ⁶⁶	13.54	ATRX CCND1 CDK4 CDKN2A CDKN2B MCM3
6	Prolactin Signaling ⁶⁴ Show member pathways Development Prolactin receptor signaling ²² EGFR Inhibitor Pathway, Pharmacodynamics ⁶⁰ EGFR tyrosine kinase inhibitor resistance ⁷⁴ ErbB Family Pathway ⁶⁴ ErbB signaling pathway ⁷⁴ ErbB2-ErbB3 Heterodimers ⁶⁴ ErbB4 Pathway ⁶⁴ Estrogen-stimulated signaling through PRKCZ ⁶⁶ Glioblastoma Multiforme ⁶⁴ Glioblastoma signaling pathways ⁷⁴ Growth Hormone Signaling ⁶⁴ HMGB1 Pathway ⁶⁴ IL-2 Pathway ⁶⁴ LPS Stimulated MAPK Signaling ⁶⁴ PACAP Signaling ⁶⁴ PI3K Signaling in B-Lymphocyte ⁶⁴ TCA cycle nutrient use and invasiveness of ovarian cancer ⁷⁴ Thrombopoietin Pathway ⁶⁴ TREM1 Pathway ⁶⁴ UVA-Induced MAPK Signaling ⁶⁴ UVB-Induced MAPK Signaling ⁶⁴ UVC-Induced MAPK Signaling ⁶⁴	13.45	CCND1 CDK4 CDKN2A CDKN2B EGFR MDM2
7	PI3K-Akt signaling pathway ⁷⁴ Show member pathways Focal adhesion: PI3K-Akt-mTOR-signaling pathway ⁷⁴	12.97	CCND1 CDK4 EGFR MDM2 PDGFRA PTEN
8	TNFR1 Pathway ⁶⁴ Show member pathways Apoptosis ⁷⁴ Apoptosis and survival TNFR1 signaling pathway ²² Apoptosis modulation by HSP70 ⁷⁴ Apoptosis through Death Receptors ⁶⁴ Apoptotic Pathways Triggered By HIV1 ⁶⁴ Ceramide signaling pathway ⁶¹ DR3 Signaling ⁶⁴ GITR Pathway ⁶⁴ HIV-1 Nef: Negative effector of Fas and TNF-alpha ⁶¹ Stimulation of the cell death response by PAK-2p34 ⁶⁶ TNF Signaling ⁶⁴ TNF-related weak inducer of apoptosis (TWEAK) signaling pathway ⁷⁴ TRAIL Pathway ⁶⁴ TWEAK Pathway ⁶⁴	12.95	VEGFA TP73 TP53 PTEN MDM2 EGFR
9	Cellular Senescence ⁶⁶ Show member pathways Oxidative Stress Induced Senescence ⁶⁶ Senescence-Associated Secretory Phenotype (SASP) ⁶⁶	12.76	TP53 MDM2 CDKN2B CDKN2A CDK4
10	Endometrial cancer ⁷⁴ Show member pathways Chromosomal and microsatellite instability in colorectal cancer ⁷⁴ Melanoma ⁷⁴ Non-small cell lung cancer ⁷⁴ Pancreatic adenocarcinoma pathway ⁷⁴ Signal transduction PTEN pathway ²²	12.66	VEGFA TP53 PTEN MDM2 EGFR CDKN2A
11	Chks in Checkpoint Regulation ⁶⁴ Show member pathways DNA Repair Mechanisms ⁶⁴ Estrogen-mediated S-Phase Entry ⁶⁴ G2-M Phase Transition ⁶⁴ SREBP Proteolysis ⁶⁴	12.64	CCND1 CDK4 MDM2 MGMT TP53
12	Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects ⁶⁶ Show member pathways Aberrant regulation of mitotic cell cycle due to RB1 defects ⁶⁶ Aberrant regulation of mitotic exit in cancer due to RB1 defects ⁶⁶ Cell cycle Cell cycle (generic schema) ²² Cell cycle Regulation of G1/S transition (part 2) ²² Cyclin D associated events in G1 ⁶⁶ Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) ⁶⁶ Defective translocation of RB1 mutants to the nucleus ⁶⁶ Diseases of mitotic cell cycle ⁶⁶ Drug-mediated inhibition of CDK4/CDK6 activity ⁶⁶ G1 Phase ⁶⁶ G2 Phase ⁶⁶ Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes ⁶⁶ PTK6 Regulates Cell Cycle ⁶⁶	12.54	CDKN2B CDKN2A CDK4 CCND1 ATRX
13	Mitotic G1 phase and G1/S transition ⁶⁶ Show member pathways G1/S Transition ⁶⁶	12.52	MCM3 CDKN2B CDKN2A CDK4 CCND1
14	NF-kappaB Pathway ⁷⁰ Show member pathways Akt Pathway ⁷⁰ Apoptosis Pathway ⁷⁰	12.45	TP53 PDGFRA MDM2 EGFR
15	Breast cancer pathway ⁷⁴ Show member pathways Embryonic stem cell pluripotency pathways ⁷⁴	12.43	TP53 PTEN PDGFRA MDM2 EGFR CDK4
16	Malignant pleural mesothelioma ⁷⁴	12.42	CCND1 CDK4 CDKN2A EGFR MDM2 PDGFRA
17	Cell cycle Regulation of G1/S transition (part 1) ²² Show member pathways Cell cycle ESR1 regulation of G1/S transition ²² Cell cycle Role of SCF complex in cell cycle regulation ²² Immune response MIF-JAB1 signaling ²² Mitotic Roles of Polo Like Kinases ⁶⁴	12.39	CDKN2B CDKN2A CDK4 CCND1
18	DNA Damage ³	12.39	TP73 TP53 MGMT MDM2 MCM3 CDKN2A
19	Focal adhesion ⁷⁴	12.33	VEGFA PTEN PDGFRA EGFR CCND1
20	Development IGF-1 receptor signaling ²² Show member pathways Immune response IL-4 signaling pathway ²² Signal transduction AKT signaling ²²	12.29	TP53 PTEN MDM2 CCND1
21	p53 Signaling ⁶⁴ Show member pathways p53 Pathway ⁶⁷	12.26	TP53 PTEN MDM2 CDK4 CCND1
22	Colorectal Cancer Metastasis ⁶⁴	12.22	VEGFA TP53 EGFR CCND1
23	MAPK Signaling: Mitogens ⁶⁵ Show member pathways Akt Signaling Pathway ⁶⁵	12.22	CCND1 CDK4 EGFR MDM2 PDGFRA PTEN
24	T-cell activation SARS-CoV-2 ⁷⁴ Show member pathways T-cell antigen receptor (TCR) pathway during Staphylococcus aureus infection ⁷⁴	12.2	TP53 PTEN CDKN2A CDK4 CCND1
25	Cell cycle ⁷⁴ Show member pathways G1 to S cell cycle control ⁷⁴	12.18	CCND1 CDK4 CDKN2A CDKN2B MCM3 MDM2
26	Transcription Androgen Receptor nuclear signaling ²² Show member pathways Translation Non-genomic (rapid) action of Androgen Receptor ²²	12.16	PTEN MDM2 EGFR CCND1
27	Cyclins and Cell Cycle Regulation ⁶⁴ Show member pathways Cell Cycle Control by BTG Proteins ⁶⁴ G1-S Phase Transition ⁶⁴	12.16	TP53 CDKN2B CDKN2A CDK4 CCND1
28	miRNA regulation of DNA damage response ⁷⁴ Show member pathways DNA damage response ⁷⁴	12.15	TP53 MDM2 CDK4 CCND1
29	mTOR Signaling ⁶⁵	12.13	TP53 PTEN PDGFRA EGFR
30	Direct p53 effectors ⁶¹	12.1	EGFR MDM2 PTEN TP53 TP73
31	Spinal cord injury ⁷⁴	12.05	TP53 GFAP EGFR CDK4 CCND1
32	Gastrin signaling pathway ⁷⁴	12.02	VEGFA EGFR CDKN2A CCND1
33	Senescence and autophagy in cancer ⁷⁴	11.98	TP53 PTEN MDM2 CDKN2A
34	DNA damage response (only ATM dependent) ⁷⁴	11.98	TP73 TP53 PTEN MDM2 CCND1
35	Integrated breast cancer pathway ⁷⁴	11.98	VEGFA TP53 PTEN MDM2 EGFR CDK4
36	DNA IR-double strand breaks and cellular response via ATM ⁷⁴ Show member pathways ATM pathway ⁶¹ DNA damage_DNA-damage-induced responses ²²	11.95	TP73 TP53 MDM2 CDKN2A
37	Small cell lung cancer ⁷⁴	11.95	TP53 PTEN CDKN2B CDK4 CCND1
38	Clear cell renal cell carcinoma pathways ⁷⁴	11.88	EGFR PDGFRA PTEN VEGFA
39	Retinoblastoma gene in cancer ⁷⁴	11.88	TP53 MDM2 MCM3 CDK4 CCND1
40	Hippo-Merlin signaling dysregulation ⁷⁴ Show member pathways Hippo signaling regulation pathways ⁷⁴	11.87	PDGFRA EGFR CCND1
41	ATM Pathway ⁶⁴ Show member pathways ATM signaling pathway ⁷⁴	11.83	TP73 TP53 MDM2
42	Neural Stem Cells and Lineage-specific Markers ⁶⁵	11.83	VEGFA PDGFRA OLIG2 OLIG1 GFAP
43	Regulation of TP53 Expression and Degradation ⁶⁶ Show member pathways Regulation of TP53 Degradation ⁶⁶ Regulation of TP53 Expression ⁶⁶	11.79	TP53 MDM2 CDKN2A
44	AP-1 transcription factor network ⁶¹	11.78	TP53 PTEN CDKN2A CCND1
45	Transcription Ligand-dependent activation of the ESR1/SP pathway ²² Show member pathways Development Ligand-dependent activation of the ESR1/AP-1 pathway ²²	11.75	VEGFA EGFR CCND1
46	Transcription_P53 signaling pathway ²²	11.75	VEGFA TP53 MDM2 CDKN2A
47	E2F transcription factor network ⁶¹	11.72	CDKN2A MCM3 TP73
48	Pathways affected in adenoid cystic carcinoma ⁷⁴	11.7	TP53 PTEN ATRX
49	DYRK1A ⁷⁴	11.69	TP53 CDK4 CCND1
50	Copper homeostasis ⁷⁴ Show member pathways Copper metabolism ⁷⁴ Defective SLC11A2 causes hypochromic microcytic anemia, with iron overload 1 (AHMIO1) ⁶⁶	11.69	TP53 PTEN MDM2 CCND1

Sources

GO Terms for Anaplastic Astrocytoma

Cellular components related to Anaplastic Astrocytoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	cyclin D1-CDK4 complex	GO:0097128	8.92	CDK4 CCND1

Biological processes related to Anaplastic Astrocytoma according to GeneCards Suite gene sharing:

(show all 13)

#	Name	GO ID	Score	Top Affiliating Genes
1	negative regulation of apoptotic process	GO:0043066	10.26	VEGFA TP53 PTEN MGMT MDM2 EGFR
2	response to xenobiotic stimulus	GO:0009410	10.11	TP73 TP53 MGMT CDK4 CCND1
3	cellular response to hypoxia	GO:0071456	10.08	MDM2 PTEN TP53 VEGFA
4	positive regulation of cell population proliferation	GO:0008284	9.97	CCND1 CDK4 EGFR MDM2 PDGFRA PTEN
5	negative regulation of cyclin-dependent protein serine/threonine kinase activity	GO:0045736	9.88	PTEN CDKN2B CDKN2A
6	positive regulation of transcription from RNA polymerase II promoter in response to hypoxia	GO:0061419	9.8	VEGFA TP53
7	cellular response to actinomycin D	GO:0072717	9.73	TP53 MDM2
8	positive regulation of phosphorylation	GO:0042327	9.67	EGFR PDGFRA VEGFA
9	cell cycle	GO:0007049	9.65	TP73 TP53 MCM3 CDKN2B CDKN2A CDK4
10	response to UV-A	GO:0070141	9.62	EGFR CCND1
11	positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway	GO:0038091	9.56	VEGFA PDGFRA
12	positive regulation of miRNA maturation	GO:1903800	9.51	TP53 EGFR
13	regulation of cell cycle	GO:0051726	9.4	TP73 TP53 PTEN MDM2 CDKN2A CDK4

Molecular functions related to Anaplastic Astrocytoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	protein kinase binding	GO:0019901	9.93	TP73 TP53 PTEN CDKN2B CDKN2A CCND1
2	disordered domain specific binding	GO:0097718	9.35	TP53 MDM2 CDKN2A
3	kinase activity	GO:0016301	9.1	PDGFRA EGFR CDKN2B CDKN2A CDK4 CCND1